Characteristics of extensive chronic GVHD at the time of diagnosis, according to transplant arm
Characteristic . | BMT (n = 32) . | PBSCT (n = 39) . |
---|---|---|
Time to chronic GVHD after transplantation, median d (range) | 136 (75-434) | 170 (76-539) |
Type of onset, no. (%) | ||
Progressive | 5 (16) | 4 (10) |
Quiescent | 15 (47) | 20 (51) |
De novo | 12 (38) | 15 (38) |
Platelets < 100 × 109/L, no. (%) | 14 (44) | 12 (31) |
Treatment with prednisone, no. (%) | 11 (34) | 13 (33) |
Treatment with other immunosuppressive agents, no. (%) | 25 (78) | 27 (69) |
Extent of skin involvement, no. (%) | ||
None | 20 (62) | 26 (67) |
No more than 50% BSA | 6 (19) | 9 (23) |
50% or more of BSA | 6 (19) | 4 (10) |
Presence of any high-risk features, no. (%)* | 19 (59) | 15 (38) |
a. Skin involvement > 50% BSA alone | 2 (6) | 2 (5) |
b. Platelet count of < 100 × 109/L alone | 11 (34) | 9 (23) |
c. Progressive-type of onset alone | 1 (3) | 1 (3) |
d. a plus b or c | 3 (9) | 0 (0) |
e. a plus b plus c | 1 (3) | 2 (5) |
f. b and c | 1 (3) | 1 (3) |
Characteristic . | BMT (n = 32) . | PBSCT (n = 39) . |
---|---|---|
Time to chronic GVHD after transplantation, median d (range) | 136 (75-434) | 170 (76-539) |
Type of onset, no. (%) | ||
Progressive | 5 (16) | 4 (10) |
Quiescent | 15 (47) | 20 (51) |
De novo | 12 (38) | 15 (38) |
Platelets < 100 × 109/L, no. (%) | 14 (44) | 12 (31) |
Treatment with prednisone, no. (%) | 11 (34) | 13 (33) |
Treatment with other immunosuppressive agents, no. (%) | 25 (78) | 27 (69) |
Extent of skin involvement, no. (%) | ||
None | 20 (62) | 26 (67) |
No more than 50% BSA | 6 (19) | 9 (23) |
50% or more of BSA | 6 (19) | 4 (10) |
Presence of any high-risk features, no. (%)* | 19 (59) | 15 (38) |
a. Skin involvement > 50% BSA alone | 2 (6) | 2 (5) |
b. Platelet count of < 100 × 109/L alone | 11 (34) | 9 (23) |
c. Progressive-type of onset alone | 1 (3) | 1 (3) |
d. a plus b or c | 3 (9) | 0 (0) |
e. a plus b plus c | 1 (3) | 2 (5) |
f. b and c | 1 (3) | 1 (3) |
P = .08.